United States - English - NLM (National Library of Medicine)

emd serono, inc. - interferon beta-1a (unii: xro4566q4r) (interferon beta-1a - unii:xro4566q4r) - interferon beta-1a 8.8 ug in 0.2 ml - rebif is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. rebif is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation. risk summary data from a large population-based cohort study, as well as other published studies over several decades, have not identified a drug-associated risk of major birth defects with the use of interferon beta during early pregnancy. findings regarding a potential risk for low birth weight or miscarriage with the use of interferon beta in pregnancy have been inconsistent (see data) . it is unclear whether, as a class of products, administration of interferon beta therapies to pregnant animals at doses greater than those used clinically results in an increased rate of abortion. the potential for rebif to have adverse effects on em

Israel - English - Ministry of Health

merck serono ltd - interferon beta 1a - solution for injection - interferon beta 1a 44 mcg/ml - interferon beta-1a - interferon beta-1a - rebif (interferone beta-1a) is indicated for the treatment of patients with relapsing forms of multiple sclerosis to decrease the frequency of clinical exacerbations and delay the accumulation of physical disability. efficacy of rebif in chronic progressive multiple sclerosis has not been established.

Australia - English - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - peginterferon beta-1a, quantity: 94 microgram - injection, solution - excipient ingredients: arginine hydrochloride; water for injections; sodium acetate trihydrate; polysorbate 20; glacial acetic acid - plegridy is indicated for the treatment of relapsing forms of multiple sclerosis (ms) (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - peginterferon beta-1a, quantity: 125 microgram - injection, solution - excipient ingredients: sodium acetate trihydrate; water for injections; glacial acetic acid; arginine hydrochloride; polysorbate 20 - plegridy is indicated for the treatment of relapsing forms of multiple sclerosis (ms) (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - peginterferon beta-1a, quantity: 94 microgram - injection, solution - excipient ingredients: glacial acetic acid; polysorbate 20; arginine hydrochloride; sodium acetate trihydrate; water for injections - plegridy is indicated for the treatment of relapsing forms of multiple sclerosis (ms) (see clinical trials).

Australia - English - Department of Health (Therapeutic Goods Administration)

biogen australia pty ltd - peginterferon beta-1a, quantity: 125 microgram - injection, solution - excipient ingredients: sodium acetate trihydrate; glacial acetic acid; water for injections; polysorbate 20; arginine hydrochloride - plegridy is indicated for the treatment of relapsing forms of multiple sclerosis (ms) (see clinical trials).

United States - English - NLM (National Library of Medicine)

guna spa - aldesleukin (unii: m89n0q7eqr) (aldesleukin - unii:m89n0q7eqr), everlasting extract (unii: kqv867adr4) (everlasting extract - unii:kqv867adr4), fomitopsis pinicola fruiting body (unii: 30d02u2irn) (fomitopsis pinicola fruiting body - unii:30d02u2irn), interferon gamma-1b (unii: 21k6m2i7ag) (interferon gamma-1b - unii:21k6m2i7ag), metenkefalin (unii: 9jez9od3as) (metenkefalin - unii:9jez9od3as), reishi (unii: tkd8lh0x2z) (reishi - unii:tkd8lh0x2z), brown rice (unii: 659g217hpg) (brown rice - unii:659g - aldesleukin 5 [hp_c] in 4 g - beta endorphin        4c    pain reliever blood            4c    immune support interferon  gamma    3c    immune support interleukin 2        5c    immune support life everlasting    3x    cold sores ling chin mushroom    8x    immune support lymphatic  gland    4c 7c    immune support melatonin        4c 15c    antioxidant rice            3x    immune support serotonin        6x    neurotransmitter soybean            3x    antioxidant spleen            4c    immune support turkey tail        8x    antioxidant temporary relief of symptoms due to viral infection such as: - upper respiratory congestion - sore throat - cold sores

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

bayer plc - interferon beta-1b - powder and solvent for solution for injection - 300microgram

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

bayer co. (malaysia) sdn. bhd. - interferon beta-1b -

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - peginterferon alfa-2b (unii: g8rgg88b68) (peginterferon alfa-2b - unii:g8rgg88b68) - peginterferon alfa-2b 40 ug in 0.1 ml - sylatron™ is an alpha interferon indicated for the adjuvant treatment of melanoma with microscopic or gross nodal involvement within 84 days of definitive surgical resection including complete lymphadenectomy. sylatron is contraindicated in patients with: - a history of anaphylaxis to peginterferon alfa-2b or interferon alfa-2b - autoimmune hepatitis - hepatic decompensation (child-pugh score >6 [class b and c]) risk summary based on findings from animal studies, sylatron can cause embryo-fetal harm when administered to a pregnant woman. available human data with sylatron use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. administration of nonpegylated interferon alfa-2b was abortifacient in rhesus monkeys at doses approximately 13 times higher than the recommended dose of 6 mcg/kg/week (see data ). in the u.s. general population, the estimated background risk of major birth defects and miscarriage is 2-4% and